Live from the NIH registry
Studies recruiting near Amarillo right now
Top 25 of 101 recruiting studies, sorted by proximity — each links to its official registry page
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Limited Stage Small Cell Lung Cancer
Phase 2
Interventional 250 participants sought
Texas Oncology - West Texas — Amarillo, Texas (1.6 mi)
· Sponsor: SCRI Development Innovations, LLC
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Breast Cancer
Phase 3
Interventional 400 participants sought
Texas Oncology-West Texas — Amarillo, Texas (1.6 mi)
· Sponsor: Pfizer
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Phase 2
Interventional 405 participants sought
Amarillo Center for Clinical Research — Amarillo, Texas (1.6 mi)
· Sponsor: Boehringer Ingelheim
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Phase 3
Interventional 10,000 participants sought
PharmaTex Research, LLC — Amarillo, Texas (1.6 mi)
· Sponsor: Novo Nordisk A/S
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic
Phase 3
Interventional 680 participants sought
Texas Oncology-West Texas — Amarillo, Texas (1.6 mi)
· Sponsor: Pfizer
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
Heart Failure
Phase 2
Interventional 200 participants sought
Amarillo Medical Specialists — Amarillo, Texas (1.6 mi)
· Sponsor: Novo Nordisk A/S
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 626 participants sought
Local Institution - 007-554G — Amarillo, Texas (1.6 mi)
· Sponsor: Mirati Therapeutics Inc.
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor
Phase 2
Interventional 256 participants sought
Texas Tech University Health Sciences Center-Amarillo — Amarillo, Texas (1.6 mi)
· Sponsor: Children's Oncology Group
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Obesity
Phase 3
Interventional 1,150 participants sought
Amarillo Medical Specialists — Amarillo, Texas (1.6 mi)
· Sponsor: Novo Nordisk A/S
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Obesity, Heart Failure
Phase 3
Interventional 5,610 participants sought
PharmaTex Research, LLC — Amarillo, Texas (1.6 mi)
· Sponsor: Novo Nordisk A/S
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
Overweight, Obesity
Phase 3
Interventional 950 participants sought
Amarillo Medical Specialists — Amarillo, Texas (1.6 mi)
· Sponsor: Novo Nordisk A/S
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Phase 3
Interventional 1,350 participants sought
89bio Clinical Study Site — Amarillo, Texas (1.6 mi)
· Sponsor: Hoffmann-La Roche
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Phase 4
Interventional 6,000 participants sought
PharmaTex Research — Amarillo, Texas (1.6 mi)
· Sponsor: Duke University
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Atherosclerotic Cardiovascular Disease, Overweight
Phase 3
Interventional 12,800 participants sought
PharmaTex Research, LLC — Amarillo, Texas (1.6 mi)
· Sponsor: Amgen
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
The Don and Sybil Harrington Cancer Center — Amarillo, Texas (1.6 mi)
· Sponsor: SWOG Cancer Research Network
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
COPD (Chronic Obstructive Pulmonary Disease)
Phase 3
Interventional 5,250 participants sought
Research Site — Amarillo, Texas (1.6 mi)
· Sponsor: AstraZeneca
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Intestinal Neoplasms, Gastrointestinal Neoplasms
Phase 3
Interventional 800 participants sought
Texas Oncology - West Texas — Amarillo, Texas (1.6 mi)
· Sponsor: Pfizer
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Viral Lung Infection and Acute Respiratory Failure
Phase 3
Interventional 3,527 participants sought
Research Site — Amarillo, Texas (1.6 mi)
· Sponsor: AstraZeneca
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Recurrent or Metastatic Solid Tumors
Phase 1, Phase 2
Interventional 680 participants sought
Texas Oncology - West Texas — Amarillo, Texas (1.6 mi)
· Sponsor: Daiichi Sankyo
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Obesity, Type 2 Diabetes
Phase 3
Interventional 2,500 participants sought
Amarillo Med Spec LLP — Amarillo, Texas (1.6 mi)
· Sponsor: Novo Nordisk A/S
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Phase 3
Interventional 5,951 participants sought
Texas Tech University Health Sciences Center-Amarillo — Amarillo, Texas (1.6 mi)
· Sponsor: Children's Oncology Group
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Phase 3
Interventional 10,450 participants sought
PharmaTex Research — Amarillo, Texas (1.6 mi)
· Sponsor: Eli Lilly and Company
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Phase 3
Interventional 1,530 participants sought
Harrington Cancer Center ( Site 0061) — Amarillo, Texas (1.6 mi)
· Sponsor: Merck Sharp & Dohme LLC
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD)
Phase 3
Interventional 480 participants sought
Southwest Retina Specialist - Panhandle Eye group, LLP — Amarillo, Texas (1.6 mi)
· Sponsor: 4D Molecular Therapeutics
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NASH With Fibrosis, MASH With Fibrosis
Phase 3
Interventional 1,650 participants sought
Akero Clinical Study Site — Amarillo, Texas (1.6 mi)
· Sponsor: Akero Therapeutics, Inc